Indegene Ltd (INDGN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Indegene Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of the Q2 FY27 Earnings Call
Transcript · 04 Nov 2026, 3:03 am
Audio Recording of the Q2 FY27 Earnings Call
Audio / Video · 30 Oct 2026, 5:44 pm
Indegene Releases Audio Recording for Q2 & H1 FY27 Earnings Call Indegene Limited has made available the audio recording of its earnings conference call for the second quarter and half-year ended 30th Sep'26. The call was conducted on 30th Oct'26 pursuant to SEBI Listing Obligations and Disclosure Requirements Regulations. Investors can access the audio recording directly via the company's designated portal link or through its official corporate website.
Audio Recording of the Q2 FY27 Earnings Call
Intimation · 30 Oct 2026, 5:37 pm
Indegene Releases Audio Recording for Q2 FY27 Earnings Call Indegene Limited conducted its earnings conference call on 30th Oct'26 to discuss financial performance for the second quarter and half year ended 30th Sep'26 (Q2 FY27). In compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, the company has made the complete audio recording accessible to investors and analysts via a dedicated link on its official website.
Analyst Presentation and Fact Sheet - financial results for the 2nd quarter and half year ended 30th September, 2026
Investor Presentation · 30 Oct 2026, 1:37 am
Indegene Q2'FY27 Results: Solid Revenue Growth with Stable Margins Indegene reported Q2'FY27 revenue of ₹11,223M ($117.5M), up 39.5% YoY (27.5% in USD) and 5.6% QoQ, driving H1'FY27 revenue to ₹21,854M. EBITDA rose 32.0% YoY to ₹1,873M with margins holding steady at 16.7% despite wage hikes. PAT grew 10.0% YoY to ₹1,123M. Growth was supported by strong client metrics, with active clients expanding to 107 and $1M+ accounts increasing to 59. Management expects growth momentum and margin expansion to accelerate in H2'FY27, supported by GenAI engagements and operating leverage.
Press Release
Press Release · 30 Oct 2026, 1:33 am
Indegene Delivers Strong Q2 FY27 Results Driven by Robust Revenue Growth Indegene announced its Q2 FY27 financial results for the quarter ended 30th Sep'26, reporting revenue of ₹11,223M ($117.5M), up 39.5% YoY (27.5% YoY in USD terms) and 5.6% QoQ. EBITDA rose 32.0% YoY to ₹1,873M with a 16.7% margin, remaining stable despite annual wage hikes. PAT grew 10.0% YoY to ₹1,123M with a 10.0% margin. The company expanded its $1M+ client base by 5 QoQ to 59, while revenue per employee improved to $79.6K. Management expects growth and margin expansion to accelerate across H2 FY27.
Indegene Limited has informed the Exchange regarding Resignation of Ms Srishti Ramesh Kaushik as Company Secretary & Compliance Officer of the company w.e.f. December 02, 2026.
Outcome · 30 Oct 2026, 1:29 am
Intimation of Resignation of Ms. Srishti Ramesh Kaushik (M. No A21609) from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.
Change in Management · 30 Oct 2026, 1:26 am
Indegene Limited Reports Q2 FY27 Results and Leadership Changes Indegene Limited reported consolidated revenue from operations of ₹11,223 million for Q2 ended 30th Sep'26, up 39.55% YoY from ₹8,042 million and 5.57% QoQ. Consolidated net profit rose 9.99% YoY to ₹1,123 million, with diluted EPS at ₹4.64. For H1 ended 30th Sep'26, consolidated revenue grew 39.64% YoY to ₹21,854 million, while PAT reached ₹2,285 million. The Board accepted the resignations of Non-Executive Director Mark Francis Dzialga (effective 29th Oct'26) and Company Secretary & Compliance Officer Srishti Ramesh Kaushik (effective 2nd Dec'26).
Indegene Limited has informed the Exchange regarding allotment of 52194 securities pursuant to ESOP/ESPS at its meeting held on October 29, 2026
Outcome · 30 Oct 2026, 1:23 am
Allotment of shares under RSU Scheme 2020 and ESOP Scheme 2020
Others (Uncategorized) · 30 Oct 2026, 1:21 am
Indegene Q2 FY27 Results: Net Profit Rises 10% YoY to ₹1,123 Million Indegene reported consolidated revenue from operations of ₹11,223 million for the quarter ended 30th Sep'26, up 39.6% YoY from ₹8,042 million and 5.6% QoQ. Consolidated net profit reached ₹1,123 million, rising 10.0% YoY but declining 3.4% QoQ. Diluted EPS stood at ₹4.64. The board approved equity allotments under RSU and ESOP Schemes 2020 and accepted resignations of Non-Executive Director Mark Francis Dzialga, following Brighton Park Capital’s full stake sale, and Company Secretary Srishti Ramesh Kaushik, effective 2nd Dec'26.
Unaudited Financial Results for the 2nd quarter and half year ended 30th September 2026
Financial Result · 30 Oct 2026, 1:14 am
Indegene Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 1:10 am
Outcome of the Board Meeting
Outcome · 30 Oct 2026, 1:07 am
Indegene Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 11,223 (+39.6% YoY | +5.6% QoQ) ■ EBITDA: 1,857 (+32.1% YoY | +6.6% QoQ) ■ EBITDA Margin (%): 16.5 (-94 bps YoY | +16 bps QoQ) ■ PAT: 1,123 (+10.0% YoY | -3.4% QoQ) ■ EPS (INR): 4.64 (+9.7% YoY | -3.5% QoQ) Indegene Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Enterprise Medical Solutions ■ Revenue: 2,753 (+22.8% YoY | +0.6% QoQ) ■ EBIT: 626 (+8.9% YoY | -12.6% QoQ) ■ EBIT Margin (%): 22.7 (-291 bps YoY | -343 bps QoQ) Enterprise Commercial Solutions ■ Revenue: 8,002 (+45.2% YoY | +6.7% QoQ) ■ EBIT: 1,302 (+32.6% YoY | +8.8% QoQ) ■ EBIT Margin (%): 16.3 (-154 bps YoY | +32 bps QoQ) Others ■ Revenue: 468 (+62.5% YoY | +19.1% QoQ) ■ EBIT: 3.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 0.6 (Loss to Profit YoY | Loss to Profit QoQ)
Acquisition
Others (Uncategorized) · 26 Oct 2026, 9:58 pm
Indegene Incorporates Step-Down Subsidiary in Portugal to Expand European Presence Indegene Limited announced the incorporation of a step-down wholly owned subsidiary, Indegene Portugal, Unipessoal LDA, on 23rd Oct'26. The new entity is 100% held by Indegene Ireland Limited, a direct wholly owned subsidiary of the company. Set up to establish a operational presence in Portugal, the entity will provide life sciences, healthcare, biopharmaceutical, content development, technology, clinical development, and medical affairs support services. The newly incorporated subsidiary currently has nil turnover and is yet to commence operations.
Press Release
Press Release · 22 Oct 2026, 4:07 pm
Indegene Receives Frost & Sullivan 2026 Global AI Pharma Leadership Recognition Indegene has received Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-powered pharma commercialization services on 22nd Oct'26. The recognition highlights Indegene's strategy effectiveness, execution scale, and proprietary solutions like its Pharma Operating System and Cortex reasoning engine across commercial, medical, regulatory, and analytics workflows. Currently trusted by the world's top 20 biopharma companies, the recognition validates Indegene’s competitive positioning, enterprise generative AI capabilities, and domain-led operating model within the global life sciences technology and commercialization landscape.
Resignation of Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive Non Independent Director of the Company
Change in Management · 15 Oct 2026, 6:28 pm
Indegene Announces Resignation of Director Mark Francis Dzialga Following Shareholding Exit Indegene Limited announced that Mr. Mark Francis Dzialga has resigned from his position as Non-Executive, Non-Independent Director, effective at the close of business on 29th Oct'26. The resignation follows the complete sale of shareholding in Indegene by Brighton Park Capital and its affiliated investment vehicles. Consequently, Mr. Dzialga will also step down from his roles on the company's Nomination and Remuneration Committee and Investment Committee effective 29th Oct'26. No other material reasons were cited for his departure.
Allotment of ESOP shares
Others (Uncategorized) · 09 Oct 2026, 12:35 am
Indegene Approves Equity Share Allotment Under ESOP Scheme 2020 Indegene Limited's Board of Directors approved the allotment of 16,110 equity shares having a face value of INR 2 each under the company's ESOP Scheme 2020 via a circular resolution passed on 5th Oct'26. The newly allotted shares will rank pari-passu with the existing equity shares of the company in all respects. Additionally, the Board approved amendments to the company's Prevention of Sexual Harassment Policy.
Press Release
Press Release · 06 Oct 2026, 8:52 pm
Indegene Highlights AI-Native Life Sciences Capabilities at Digital Summit 2026 Indegene filed supplementary disclosures on 6th Oct'26 regarding its Indegene Digital Summit 2026 held in Philadelphia. The event gathered 120+ senior life sciences leaders (50%+ decision-makers, 70% Director+) and 19 speakers, marking a 40% increase in pharma participation compared to 2025 across 410+ minutes of sessions. Discussions centered on operationalizing AI at scale, workflow redesign, and evidence-led engagement. The summit highlighted Indegene’s proprietary AI platform capabilities—spanning Agentic AOR, Content Super App, and Audience IQ—reinforcing its enterprise positioning and client traction within the US biopharma ecosystem.
INDEGENE LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 29 Oct 2026, 5:30 am
Intimation of Indegene Limited Q2 FY27 Earnings Call
Intimation · 30 Oct 2026, 8:00 am
Indegene Schedules Q2 FY27 Earnings Conference Call for 30th Oct'26 Indegene Limited will host its Q2 FY27 earnings conference call on Friday, 30th Oct'26 at 8:00 AM IST. Senior management, including Chairman and CEO Manish Gupta along with CFO Suhas Prabhu, will address participants to discuss the company's financial performance. Universal dial-in numbers for the call are +91 22 6280 1162 and +91 22 7115 8063, with pre-registration available via Diamond Pass.
Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Intimation · 29 Oct 2026, 5:30 am
Indegene Schedules Board Meeting on 29th Oct'26 to Consider Q2 Results and Share Allotments Indegene Limited will hold its Board of Directors meeting on 29th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, along with the limited review report. The board will also consider share allotments under its RSU Scheme 2020 and ESOP Scheme 2020. The trading window for company securities closes from 1st Oct'26 until 48 hours post the declaration of the financial results.
Press Release
Press Release · 23 Sept 2026, 11:25 pm
Indegene Concludes Digital Summit 2026 Focused on AI Operationalization Indegene hosted over 200 life sciences leaders at its eighth Indegene Digital Summit in Philadelphia on 22nd Sep'26, focusing on operationalizing AI to translate investments into measurable P&L and commercial outcomes. Discussions centered on transitioning to life-sciences-native operating models to enhance drug discovery, clinical research, personalized customer engagement, and product launches. Additionally, the company presented the second edition of the VITAL Awards, recognizing executives across global biopharma leaders, including Bayer, Vertex, Gilead Sciences, BioMarin, and Incyte, for driving AI-led transformational, organizational, and market impacts.
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 - Merger of Indirect Wholly owned subsidiaries of the Company in Germany
Others (Uncategorized) · 11 Sept 2026, 1:20 am
Indegene Completes Internal Merger of Wholly Owned German Subsidiaries Indegene Limited announced the merger of its indirect wholly owned subsidiaries in Germany, Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, effective 9th Sep'26. Following the merger, Trilogy Writing & Consulting GmbH emerged as the surviving entity and was subsequently renamed Indegene Healthcare Germany GmbH. The surviving entity's projected revenue for FY26-27 stands at €20.10mn. Undertaken as an internal restructuring, the transaction involves no cash consideration, share exchange, or change in Indegene's shareholding pattern, with no material impact on the company's financials or business operations.
Intimation of Investors / Analysts Meeting
Intimation · 08 Sept 2026, 5:32 pm
Indegene Limited Schedules 1-on-1 Investor Meeting with Premji Invest Indegene Limited announced an in-person, 1-on-1 investor/analyst meeting with Premji Invest scheduled for 11th Sep'26 in Bengaluru, Karnataka. The company confirmed that no unpublished price-sensitive information will be shared during the interaction.
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly- Owned Subsidiary, Indegene, Inc.
Others (Uncategorized) · 31 Aug 2026, 11:33 pm
Indegene: US Subsidiary Class Action Settlement Preliminarily Approved Indegene's US subsidiary, Indegene, Inc., received preliminary court approval on 27 Aug'26 for a proposed class-action settlement. The settlement framework includes a maximum fund of approx. USD 4.72M, with actual payments contingent on valid claims. The company is not required to pre-fund the amount. Final approval from the U.S. District Court, District of New Jersey, is scheduled for 12 Jan'27, following the completion of the notice and claims process. The actual financial impact depends on the number of approved claims and associated costs.
Intimation of Investors / Analysts Meeting
Intimation · 19 Aug 2026, 9:16 pm
Indegene Announces Investor and Analyst Meeting Schedule Indegene announced its schedule for upcoming investor meetings. On 24 Aug'26, the company will hold online meetings with MFS International Singapore, ASK Investment Managers, and Mirae Mutual Fund. On 25 Aug'26, an in-person meeting is scheduled with Goldman Sachs Asset Management in Bengaluru, followed by an online meeting with Seven Canyon Advisors. Indegene confirmed that no unpublished price-sensitive information will be shared during these interactions. The schedule is subject to change.